Market Cap 106.10M
Revenue (ttm) 0.00
Net Income (ttm) -40.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 160,300
Avg Vol 134,986
Day's Range N/A - N/A
Shares Out 12.24M
Stochastic %K 24%
Beta 3.11
Analysts Strong Sell
Price Target $42.89

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 963 0100
Fax: 617 663 6085
Address:
500 River Ridge Drive, Norwood, United States
shlomiko
shlomiko Jun. 26 at 3:53 PM
0 · Reply
MGBuckeye
MGBuckeye Jun. 26 at 3:51 PM
$CRBP down nearly 10%. Why?
0 · Reply
RlCK
RlCK Jun. 25 at 10:32 PM
$CRBP average at 78. Almost there! 😂😂😂
0 · Reply
Cricket23
Cricket23 Jun. 25 at 6:50 PM
$CRBP Very strong move to the upside from CRBP today on high volume! This has lots of room to run much higher! Their pipeline of products they offer is very valuable.
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 19 at 5:59 AM
$CRBP Corbus’ experimental drug CRB-701 targets a hot oncology pathway. With a long cash runway, CRBP might be massively undervalued. https://biotechhealthx.com/biotech-news/corbus-crbp-has-149m-in-cash-a-cancer-drug-that-could-shock-wall-street/
0 · Reply
sageinvestor
sageinvestor Jun. 18 at 3:19 PM
$CRBP https://www.ainvest.com/news/slimming-odds-corbus-crb-913-outpace-novo-monlunabant-obesity-market-2506/
0 · Reply
birdmine
birdmine Jun. 13 at 12:06 PM
$CRBP 9.50 in the premarket. Can it hit 10?
0 · Reply
MoneyMcDuck
MoneyMcDuck Jun. 11 at 6:23 PM
$CRBP is setting up cleanly—price recently reclaimed key moving averages and continues to grind higher off April lows. Trend strength is intact, even without a major volume spike. Their lead program targets cancer and metabolic disease with a novel mTORC1 inhibitor. With $130M+ in cash and no debt, they’re funded deep into 2027. ✅ Low float ✅ Bullish structure ✅ $6B+ target market Watch dips near $8.60 or strength above $9.30. Solid setup with room to run. 🔥
1 · Reply
Bornjever
Bornjever Jun. 11 at 1:50 PM
$CRBP similar in less dramatic way is ARQT with focus on skin disease but really helping people with 4th approval came on 0522 and stock price actually dropped with shorts being ones to see small bio without flashy cancer meds with 350 million or more in 2025 revenue and 450 million in 2026 but each time more revenue price goes down and you just have to know what you hold and eventually you will be rewarded VERY
0 · Reply
shoagh12
shoagh12 Jun. 9 at 11:24 AM
$CRBP Double up today
0 · Reply
Latest News on CRBP
Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering


Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering


Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug


shlomiko
shlomiko Jun. 26 at 3:53 PM
0 · Reply
MGBuckeye
MGBuckeye Jun. 26 at 3:51 PM
$CRBP down nearly 10%. Why?
0 · Reply
RlCK
RlCK Jun. 25 at 10:32 PM
$CRBP average at 78. Almost there! 😂😂😂
0 · Reply
Cricket23
Cricket23 Jun. 25 at 6:50 PM
$CRBP Very strong move to the upside from CRBP today on high volume! This has lots of room to run much higher! Their pipeline of products they offer is very valuable.
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 19 at 5:59 AM
$CRBP Corbus’ experimental drug CRB-701 targets a hot oncology pathway. With a long cash runway, CRBP might be massively undervalued. https://biotechhealthx.com/biotech-news/corbus-crbp-has-149m-in-cash-a-cancer-drug-that-could-shock-wall-street/
0 · Reply
sageinvestor
sageinvestor Jun. 18 at 3:19 PM
$CRBP https://www.ainvest.com/news/slimming-odds-corbus-crb-913-outpace-novo-monlunabant-obesity-market-2506/
0 · Reply
birdmine
birdmine Jun. 13 at 12:06 PM
$CRBP 9.50 in the premarket. Can it hit 10?
0 · Reply
MoneyMcDuck
MoneyMcDuck Jun. 11 at 6:23 PM
$CRBP is setting up cleanly—price recently reclaimed key moving averages and continues to grind higher off April lows. Trend strength is intact, even without a major volume spike. Their lead program targets cancer and metabolic disease with a novel mTORC1 inhibitor. With $130M+ in cash and no debt, they’re funded deep into 2027. ✅ Low float ✅ Bullish structure ✅ $6B+ target market Watch dips near $8.60 or strength above $9.30. Solid setup with room to run. 🔥
1 · Reply
Bornjever
Bornjever Jun. 11 at 1:50 PM
$CRBP similar in less dramatic way is ARQT with focus on skin disease but really helping people with 4th approval came on 0522 and stock price actually dropped with shorts being ones to see small bio without flashy cancer meds with 350 million or more in 2025 revenue and 450 million in 2026 but each time more revenue price goes down and you just have to know what you hold and eventually you will be rewarded VERY
0 · Reply
shoagh12
shoagh12 Jun. 9 at 11:24 AM
$CRBP Double up today
0 · Reply
StockStratigizer
StockStratigizer Jun. 6 at 6:50 PM
GLMD meets a lot of criteria 🔥 Biotech history shows what’s possible when the right setup meets the right spark… 📈 $RCUS$2 to $25+ on oncology momentum 📈 $CRBP$0.90 to $9+ on FDA buzz 📈 $XBIO — under $1 to $6+ on low-float madness 📈 $MRNS$1.50 to $13+ on epilepsy pipeline news ⬇️⬇️⬇️⬇️ Now look at $GLMD 🔹 Trading under $2 🔹 Book value near $12 🔹 Strong cash position 🔹 Biotech catalyst potential 🔹 Tight float 👀 Not a guarantee. Not advice. Just perspective. In biotech land, moves like these have happened before. GLMD has the ingredients. Now it’s about the catalyst.
0 · Reply
birdmine
birdmine Jun. 6 at 12:16 PM
$CRBP is it finally about to crest 9$?
0 · Reply
Cricket23
Cricket23 Jun. 3 at 6:58 PM
$CRBP Very nice gain we are seeing from CRBP today! Have been doing due diligence on this company for a while now and I strongly believe they will turn things around and shareholders will be greatly rewarded! Their pipeline of products is too valuable for this company not to get recognition. CRBP was once at $60, let's see if management can ramp things up and get the stock price back to its former glory.
2 · Reply
silentmaxx
silentmaxx Jun. 3 at 2:20 PM
0 · Reply
Burlap0
Burlap0 May. 30 at 1:33 PM
$CRBP OYE...you can't park there!
0 · Reply
LuigiDurante
LuigiDurante May. 29 at 11:19 AM
$CRBP This was over $60 stock and it dropped under $7 without any news specific to their drugs. This company also never once responded thru a press release. The management team is a joke and the stock is a dog.
1 · Reply
Cricket23
Cricket23 May. 27 at 4:30 PM
$CRBP The current stock price of CRBP is currently very low for the pipeline of products they are offering. Paytience will be rewarded with this stock. The next set of positive news will send this pushing higher. Holding Strong!
1 · Reply
WallStreetBuyDip
WallStreetBuyDip May. 24 at 11:35 PM
people asking about $CRBP just watch H% get low like shown here
0 · Reply
TalkMarkets
TalkMarkets May. 24 at 6:40 PM
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies $NVO $CRBP $SKYE Also $LLY https://talkmarkets.com/content/stocks--equities/3-stocks-targeting-weight-loss-market-with-cannabinoid-based-therapies?post=499396&userid=123969
1 · Reply
They_call_me_tater_salad
They_call_me_tater_salad May. 17 at 7:11 PM
$ACHV $AURA $CRBP I’ve selected the best prospects from a large group of companies I have watched for some time. Monday I’ll be allocating the +$500K from my INZY exit last Friday as follows: ACHV - 50% AURA - 30% CRBP - 20% 12-18 Month Target: Best case (positive BLA for ACHV + strong AURA data): combined value could exceed $1.4M Base case (ACHV approved, AURA mixed, CRBP drifts): ~$700K$1M range Worst case (AURA and CRBP disappoint, ACHV delayed or diluted): portfolio value could drop to $325K-$375K - Around a 27% chance. As always… This is simply what I am doing. It’s not advice or a recommendation. Always research thoroughly before making a personal financial or investment decision.
2 · Reply
ZacksResearch
ZacksResearch May. 16 at 6:26 PM
Is $CRBP's pipeline worth the risk? 🤔 Corbus Pharmaceuticals' lead candidate, CRB-913, shows promise in obesity treatment with a favorable brain-to-plasma ratio, but no commercial products mean a long road ahead. Shares are down 39% YTD, highlighting investor concerns over its financial position and lack of revenue. Understand the risks before investing in CRBP 👉 https://www.zacks.com/commentary/2472764/is-small-cap-corbus-pharma-a-worthy-cannabis-investment?cid=sm-stocktwits-2-2472764-body&ADID=SYND_STOCKTWITS_TWEET_2_2472764_BODY
0 · Reply
Estimize
Estimize May. 14 at 10:00 AM
Wall St is expecting -1.52 EPS for $CRBP Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/crbp?chart=historical&metric_name=eps&utm_c
0 · Reply